Cenix BioScience and Schering, Isis Pharmaceuticals, Alnylam Pharmaceuticals, Ambion Diagnostics and The Blood Center, Sigma-Aldrich and JRH Biosciences, and CombiMatrix | GenomeWeb

Cenix, Schering Ink Research Service Agreements

Cenix BioScience said this week that it has signed research service agreements with German pharmaceutical firm Schering to accelerate ongoing target discovery and validation efforts in two undisclosed human disease programs.

The deal expands on two projects begun last year under which Cenix used its technology to conduct large-scale target screening work for Schering, Cenix’s director of discovery programs, Birte Sonnichsen, told RNAi News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.